home / stock / eypt / eypt news

EYPT News and Press, EyePoint Pharmaceuticals Inc. From 07/20/21

Stock Information
Company Name: EyePoint Pharmaceuticals Inc.
Stock Symbol: EYPT
Market: NASDAQ
Website: eyepointpharma.com
Menu
EYPT EYPT Quote EYPT Short EYPT News EYPT Articles EYPT Message Board
Get EYPT Alerts

News, Short Squeeze, Breakout and More Instantly...
EYPT - EyePoint Pharmaceuticals Receives Preliminary Extension to Pass-Through Payment Status for DEXYCU®

WATERTOWN, Mass., July 20, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced today that the Company expects to ...
EYPT - EyePoint Pharma reports positive EYP-1901 results in wet-AMD

EyePoint Pharmaceuticals (EYPT) announces positive safety results from Phase 1 trial of EYP-1901, an anti-VEGF treatment targeting wet age-related macular degeneration (wet AMD). The DAVIO clinical trial of EYP-1901 enrolled 17 wet AMD patients across three dose cohorts.Key safety observation...

EYPT - EyePoint Pharmaceuticals Reports Positive 30-day Safety Results for all Cohorts from the DAVIO Trial of EYP-1901 for wet-AMD

WATERTOWN, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced positive safety results from its ...

EYPT - EyePoint Pharmaceuticals Announces New Category III CPT Code for DEXYCU® Intraocular Suspension, Approved by the American Medical Association

WATERTOWN, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced today that the American Medical As...
EYPT - EyePoint Pharmaceuticals to join Russell 2000 and 3000 Index

EyePoint Pharmaceuticals (EYPT) to join the broad-market Russell 3000 Index and the small-cap Russell 2000 Index at annual reconstitution, effective Monday, June 28, 2021.Press Release For further details see: EyePoint Pharmaceuticals to...

EYPT - EyePoint Pharmaceuticals Joins Russell 2000® and Russell 3000® Index

WATERTOWN, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced today that the Company will be add...

EYPT - EyePoint Pharmaceuticals to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference

WATERTOWN, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that Nancy Lurker, Chief Exec...
EYPT - EyePoint Pharmaceuticals Announces Completion of Enrollment of Phase 1 DAVIO Clinical Trial of EYP-1901 for the Potential Treatment of Wet AMD

WATERTOWN, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the completion of patient enr...

EYPT - EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q1 2021 Results - Earnings Call Transcript

EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2021 Earnings Conference Call May 05, 2021, 08:30 ET Company Participants George Elston - CFO & Head, Corporate Development Nancy Lurker - President, CEO & Director Jay Duker - Chief Strategic Scientific Officer Scott Jones - Chief Commercial O...

EYPT - EyePoint Pharmaceuticals EPS beats by $0.01, misses on revenue

EyePoint Pharmaceuticals (EYPT): Q1 GAAP EPS of -$0.50 beats by $0.01.Revenue of $7.3M (-2.5% Y/Y) misses by $0.54M.Financial Outlook: Expects the cash on hand at March 31, 2021 and expected net cash inflows from the product sales to fund the current and planned operations through the en...
Previous 10 Next 10